Related Experiment Videos
Neplanocin A. A cyclopentenyl analog of adenosine with specificity for inhibiting RNA methylation
Abstract:
The mechanism of action of the adenosine analog, neplanocin A (NPC), was investigated in human colon carcinoma cell line HT-29. Cell viability was reduced to 38 and 17% of control by 24-h exposure to 10(-5) and 10(-4) M NPC, respectively. Cytocidal activity was not affected by inhibition of adenosine deaminase with 2'-deoxycoformycin. Concomitant with decreased cell viability was the reduced incorporation of [14C]dThd and [3H]Leu, and to a lesser extent [3H]Urd, into acid-precipitable material. Labeling of rRNA and tRNA during drug treatment for 24 h with [methyl-3H]Met and [14C]Urd revealed that NPC primarily inhibited RNA methylation, and to a lesser extent, RNA synthesis. RNase T2 digests of total RNA indicated that base and 2'-O-methylation were inhibited to approximately the same degree. Metabolites of NPC were measured by reverse-phase high-performance liquid chromatography and it was found that the major drug metabolite was the drug analog of S-adenosylmethionine with little formation of the respective, S-adenosylhomocysteine metabolite. NPC was utilized to a very small degree for RNA synthesis where only 2 and 30 pmol of NPC/A260 were incorporated into rRNA and tRNA after 24-h exposure to 10(-5) and 10(-4) M NPC, respectively. These results indicate that NPC is metabolized to a metabolite of S-adenosylmethionine which is a poor methyl donor for RNA methyltransferases, and that the accompanying decrease in RNA methylation and protein synthesis appears to be related to its cytocidal activity.
Insights
Neplanocin A (NPC) reduces colon cancer cell viability by inhibiting RNA methylation and protein synthesis. It metabolizes into a poor methyl donor, impacting RNA methyltransferases and leading to cell death.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Adenosine analogs are investigated for anticancer properties.
- Neplanocin A (NPC) is an adenosine analog with potential cytotoxic effects.
- Understanding NPC's mechanism of action is crucial for its therapeutic development.
Purpose of the Study:
- To elucidate the mechanism of action of neplanocin A (NPC) in human colon carcinoma HT-29 cells.
- To determine the effects of NPC on cell viability, nucleic acid synthesis, and methylation.
- To identify the major metabolites of NPC and their role in its activity.
Main Methods:
- Cell viability assays were performed on HT-29 cells exposed to NPC.
- Incorporation of radiolabeled nucleosides and amino acids was measured to assess synthesis.
- RNA methylation was analyzed using radiolabeled precursors and RNase T2 digestion.
- NPC metabolites were identified using high-performance liquid chromatography.
Main Results:
- NPC significantly reduced HT-29 cell viability in a dose-dependent manner.
- NPC inhibited the incorporation of [14C]dThd, [3H]Leu, and [3H]Urd, indicating reduced DNA, protein, and RNA synthesis.
- NPC primarily inhibited RNA methylation, affecting both base and 2'-O-methylation.
- The major NPC metabolite was identified as an analog of S-adenosylmethionine, a poor methyl donor.
- NPC incorporation into rRNA and tRNA was minimal.
Conclusions:
- Neplanocin A exhibits cytocidal activity against colon carcinoma cells.
- NPC's mechanism involves metabolism to a faulty S-adenosylmethionine analog, impairing RNA methylation.
- Inhibition of RNA methylation and subsequent protein synthesis contributes to NPC's anticancer effects.